Evidence map›Paper›PMID 35747234›Full record

ReviewBiologics : targets & therapy2022

Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician.

Adam Saleh, Usman Ansari, Shaadi Abughazaleh, Kerri Glassner, Bincy P Abraham

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Biologics : targets & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Adam SalehEngineering Medicine, Texas A&M University, Houston, TX, USA.ORCID 0000-0002-1410-237X
Usman AnsariDepartment of Medicine - Division of Gastroenterology, Houston Methodist, Houston, TX, USA.
Shaadi AbughazalehDepartment of Medicine - Division of Gastroenterology, Houston Methodist, Houston, TX, USA.ORCID 0000-0003-2473-0182
Kerri GlassnerDepartment of Medicine - Division of Gastroenterology, Houston Methodist, Houston, TX, USA.
Bincy P AbrahamDepartment of Medicine - Division of Gastroenterology, Houston Methodist, Houston, TX, USA.ORCID 0000-0003-0308-1224
Houston Methodist · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Several biologic therapies have been approved for enteric diseases. We evaluate each biologic's role based on their mechanism of action in treating these conditions. This review examines data on efficacy and safety, as well as considerations for using these therapies in clinical practice in inflammatory bowel diseases, enteric infections-specifically

Indexed as

biologicsClostridioides difficile colitisCrohn’s diseaseenteric diseasemicroscopic colitisulcerative colitis

Identifiers

PMID35747234
PMCPMC9211072
OpenAlexW4283019069

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.